loading...| Preferred Name |
triazolam |
|
| Synonyms |
Gen-Triazolam Novo-Triolam Novidorm DEA No Alti-Triazolam Novodorm Triazolamum (INN-Latin) Songar Apo-Triazo 2887 Clorazolam Halcion 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine |
|
| Definitions |
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances. Pharmacology: A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites. Mechanism of action: Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Drug type: Approved. Illicit. Small Molecule. Withdrawn. Drug category: Adjuvants, Anesthesia. Anti-anxiety Agents. Benzodiazepines. GABA Modulators |
|
| ID |
http://purl.obolibrary.org/obo/CHEBI_9674 |
|
| alternative label |
Halcion 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine |
|
| charge |
0 |
|
| createdDate |
March 5, 2010 |
|
| database_cross_reference |
KEGG:D00387 Wikipedia:Triazolam Beilstein:1226643 CAS:28911-01-5 Drug_Central:2729 DrugBank:DB00897 |
|
| definition |
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances. Pharmacology: A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites. Mechanism of action: Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Drug type: Approved. Illicit. Small Molecule. Withdrawn. Drug category: Adjuvants, Anesthesia. Anti-anxiety Agents. Benzodiazepines. GABA Modulators |
|
| formula |
C17H12Cl2N4 |
|
| has characteristic | ||
| has exact synonym |
8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine |
|
| has role | ||
| has_obo_namespace |
chebi_ontology |
|
| has_related_synonym |
Halcion |
|
| hasExternalSource |
DB00897 |
|
| id |
CHEBI:9674 |
|
| in_subset | ||
| inchi |
InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 |
|
| inchikey |
JOFWLTCLBGQGBO-UHFFFAOYSA-N |
|
| label |
Triazolam triazolam |
|
| mass |
343.20954 |
|
| modifiedDate |
May 21, 2010 |
|
| monoisotopicmass |
342.04390 |
|
| notation |
CHEBI:9674 |
|
| note |
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances. Pharmacology: A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites. Mechanism of action: Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Drug type: Approved. Illicit. Small Molecule. Withdrawn. Drug category: Adjuvants, Anesthesia. Anti-anxiety Agents. Benzodiazepines. GABA Modulators |
|
| preferred label |
triazolam |
|
| prefLabel |
triazolam |
|
| smiles |
Cc1nnc2CN=C(c3ccccc3Cl)c3cc(Cl)ccc3-n12 |
|
| synonym |
Gen-Triazolam Novo-Triolam Novidorm DEA No Alti-Triazolam Novodorm Triazolamum (INN-Latin) Songar Apo-Triazo 2887 Clorazolam |
|
| subClassOf |